60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
60 Degrees Pharmaceuticals, Inc. (SXTP) trades at $1.13 with AI Score 18/100 (Grade F). 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SXTP: SXTP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SXTP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SXTP: 1/3 scored disciplines lean bearish. Dominant signal: Business Quality weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
60 Degrees Pharmaceuticals, Inc. (SXTP) Healthcare & Pipeline Overview
60 Degrees Pharmaceuticals, Inc. is a biotechnology firm specializing in infectious disease therapies, including Arakoda for malaria prevention. The company is currently developing treatments for COVID-19, babesiosis, and other viral infections, positioning it within a competitive landscape of pharmaceutical innovators.
What Is the Investment Thesis for SXTP?
60 Degrees Pharmaceuticals presents a focused investment opportunity within the infectious disease treatment space. The company's lead product, Arakoda, generates revenue through malaria prevention, while its pipeline of Tafenoquine and Celgosivir targets significant unmet needs in COVID-19, babesiosis, and Zika virus. Key value drivers include successful clinical trial outcomes for Tafenoquine, potential FDA approvals, and strategic partnerships to expand market reach. The company's small size and limited resources pose risks, requiring careful monitoring of cash burn and funding needs. The negative P/E ratio of -0.27 and a negative profit margin of -827.8% indicate that the company is currently unprofitable. The high beta of 3.03 suggests high volatility. Successful clinical trials and subsequent commercialization of its pipeline drugs are critical for long-term value creation.
Based on FMP financials and quantitative analysis
SXTP Key Highlights
Market capitalization of $0.00B indicates that the company is a micro-cap stock.
- P/E ratio of -0.27 reflects the company's current lack of profitability.
- Profit margin of -827.8% shows significant losses relative to revenue.
- Gross margin of 19.1% indicates the percentage of revenue exceeding the cost of goods sold.
- Beta of 3.03 suggests the stock is more volatile than the market average.
Who Are SXTP's Competitors?
SXTP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDRX Biodexa Pharmaceuticals Plc | $1.26 | +0.00% | 39 | |
| CLDI Calidi Biotherapeutics, Inc. | $1.34 | -2.90% | — | |
| CNSP CNS Pharmaceuticals, Inc. | $5.83 | -0.54% | $8.52M | 30 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SXTP's Key Strengths?
Specialized focus on infectious diseases.
- Existing product (Arakoda) generating revenue.
- Pipeline of drug candidates in clinical trials.
- Patent license agreement with Tufts Medical Center.
What Are SXTP's Weaknesses?
Small company size and limited resources.
- Dependence on clinical trial outcomes.
- High operating losses and negative profit margin.
- Limited commercialization capabilities.
What Could Drive SXTP Stock Higher?
Results from Phase IIb clinical trial of Tafenoquine for COVID-19.
- Results from Phase IIA clinical trials of Tafenoquine for babesiosis.
- Development of Celgosivir for Zika, respiratory viruses, and dengue.
- Expansion of Arakoda market reach and sales.
What Are the Key Risks for SXTP?
Financial-distress signal — its Altman Z-Score of -18.84 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Clinical trial failures for Tafenoquine and Celgosivir.
- Regulatory setbacks and delays in drug approvals.
- Competition from larger pharmaceutical companies.
- Funding constraints and the need for additional capital.
- Patent expirations and generic competition.
What Are the Growth Opportunities for SXTP?
- Expansion of Arakoda Market: Arakoda, the company's malaria preventative treatment, has the potential for increased market penetration. The global market for malaria prevention is substantial, driven by international travel and endemic regions. By expanding distribution channels and targeting specific traveler segments, 60 Degrees Pharmaceuticals can increase Arakoda sales. The timeline for this growth opportunity is ongoing, with continuous efforts to enhance market reach and brand awareness.
- Tafenoquine for COVID-19: The Phase IIb clinical trial of Tafenoquine for COVID-19 indications presents a significant growth opportunity. Successful trial outcomes and subsequent regulatory approval could lead to a substantial revenue stream. The COVID-19 treatment market remains relevant, particularly for vulnerable populations. The timeline for this opportunity depends on the clinical trial progress and regulatory review, with potential market entry within the next 1-2 years.
- Tafenoquine for Babesiosis: The Phase IIA clinical trials of Tafenoquine for babesiosis represent another growth avenue. Babesiosis, an emerging infectious disease, lacks effective treatments, creating a niche market opportunity. Positive clinical results and regulatory approval could establish Tafenoquine as a leading therapy for babesiosis. The timeline for this opportunity is contingent on clinical trial advancements and regulatory pathways, with potential commercialization in 2-3 years.
- Celgosivir for Zika and Dengue: The development of Celgosivir for Zika, respiratory viruses, and dengue offers a long-term growth prospect. These viral infections pose ongoing global health challenges, creating a demand for effective treatments. Successful preclinical and clinical development of Celgosivir could lead to a valuable addition to the company's product portfolio. The timeline for this opportunity extends over several years, requiring sustained research and development efforts.
- Partnerships and Licensing: Strategic partnerships and licensing agreements can accelerate the growth of 60 Degrees Pharmaceuticals. Collaborating with larger pharmaceutical companies or research institutions can provide access to funding, expertise, and distribution networks. Licensing out certain assets or technologies can generate revenue and reduce development costs. The timeline for this opportunity is flexible, depending on the company's strategic priorities and available partnership opportunities.
What Are SXTP's Competitive Advantages?
- Proprietary drug formulations and intellectual property.
- Clinical trial data and regulatory approvals.
- Patent license agreement with Tufts Medical Center.
What Does SXTP Do?
Founded in 2010 and headquartered in Washington, D.C., 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of treatments for infectious diseases. The company's primary focus is on addressing unmet needs in the prevention and treatment of diseases such as malaria, COVID-19, babesiosis, and Zika virus. Their lead product, Arakoda, is a preventative treatment for malaria, offering a crucial solution for travelers and individuals in malaria-prone regions. In addition to Arakoda, 60 Degrees Pharmaceuticals is actively engaged in clinical trials for Tafenoquine, targeting COVID-19, babesiosis, fungal pneumonias, and candidiasis. They are also developing Celgosivir for Zika, respiratory viruses, and dengue. The company has a patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. With a small team of 3 employees, 60 Degrees Pharmaceuticals operates in the competitive biotechnology sector, striving to bring innovative solutions to combat infectious diseases.
What Products and Services Does SXTP Offer?
- Develop and commercialize therapies for infectious diseases.
- Offer Arakoda for malaria preventative treatment.
- Conduct Phase IIb clinical trials for Tafenoquine in COVID-19 indications.
- Conduct Phase IIA clinical trials for Tafenoquine in babesiosis, fungal pneumonias, and candidiasis.
- Develop Celgosivir for Zika, respiratory viruses, and dengue.
- Maintain a patent license agreement with Tufts Medical Center for tafenoquine.
How Does SXTP Make Money?
- Develop and commercialize pharmaceutical products for infectious diseases.
- Generate revenue through sales of Arakoda for malaria prevention.
- Seek partnerships and licensing agreements to expand product reach and development capabilities.
What Industry Does SXTP Operate In?
60 Degrees Pharmaceuticals operates within the biotechnology industry, a sector characterized by intense research and development, regulatory hurdles, and high-risk, high-reward ventures. The infectious disease market is driven by global health threats, emerging pathogens, and the need for novel therapies. The competitive landscape includes established pharmaceutical giants and smaller biotech firms, all vying for market share. 60 Degrees Pharmaceuticals focuses on niche areas like malaria prevention and treatments for neglected tropical diseases, differentiating itself through targeted drug development.
Who Are SXTP's Key Customers?
- Travelers to malaria-prone regions.
- Individuals at risk of contracting infectious diseases.
- Healthcare providers seeking treatments for infectious diseases.
Forward Outlook
Wall Street analysts project 60 Degrees Pharmaceuticals, Inc. revenue of about $900K for fiscal 2026, with EPS near $-3.29.
Quarterly Financial Performance: 60 Degrees Pharmaceuticals, Inc.
Revenue for 60 Degrees Pharmaceuticals, Inc. came in at $208K during Q2 2026, a 28.3% improvement versus the preceding quarter. The company recorded a net loss of $2.3M, with diluted EPS of $-0.90. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, SXTP averaged $-1.51 in diluted EPS.
SXTP Valuation & Market Position
Relative to its peer group, SXTP's quantitative score of 18/100 is below the peer average of 56/100.
Financial Health
60 Degrees Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -18.84 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
60 Degrees Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 54.6% below estimates on average.
Company Profile
60 Degrees Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Washington, US. The company is led by CEO Geoffrey Stuart Dow. SXTP has traded publicly since 2023.
SXTP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on infectious diseases.
- Existing product (Arakoda) generating revenue.
- Pipeline of drug candidates in clinical trials.
- Patent license agreement with Tufts Medical Center.
Bear Case
- Small company size and limited resources.
- Dependence on clinical trial outcomes.
- High operating losses and negative profit margin.
- Limited commercialization capabilities.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $207,898 | -$2M | -$0.90 |
| Q1 2026 | $162,092 | -$2M | -$1.28 |
| Q4 2025 | $303,385 | -$1M | -$1.35 |
| Q3 2025 | $437,602 | -$2M | -$2.52 |
Based on FMP financials and quantitative analysis
SXTP Latest News
No recent news available for SXTP.
SXTP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SXTP.
Price Targets
Wall Street price target analysis for SXTP.
SXTP MoonshotScore
What does this score mean?
The MoonshotScore rates SXTP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Geoffrey Stuart Dow
CEO
Geoffrey Stuart Dow serves as the CEO of 60 Degrees Pharmaceuticals, Inc. His background includes experience in the pharmaceutical industry, with a focus on infectious disease treatments. He has been involved in the development and commercialization of pharmaceutical products. His expertise lies in strategic planning, business development, and clinical trial management. He is responsible for leading the company's overall strategy and operations.
Track Record: Under Geoffrey Stuart Dow's leadership, 60 Degrees Pharmaceuticals has focused on advancing its pipeline of drug candidates, including Arakoda and Tafenoquine. He has overseen the company's clinical trial programs and strategic partnerships. Key milestones include the commercialization of Arakoda and the progression of Tafenoquine into Phase II clinical trials. He manages a small team of 3 employees.
What Investors Ask About 60 Degrees Pharmaceuticals, Inc. (SXTP) — Healthcare
What does the AI Score mean for SXTP?
SXTP holds an AI Score of 18/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases. Their lead product, Arakoda, is used for malaria …
What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for the prevention and treatment of infectious diseases. Their lead product, Arakoda, is a preventative treatment for malaria. The company is also developing Tafenoquine for COVID-19, babesiosis, fungal pneumonias, and candidiasis, as well as Celgosivir for Zika, respiratory viruses, and dengue.
What do analysts say about SXTP stock?
There is currently no available analyst coverage for SXTP stock. Given the company's small market capitalization and limited trading volume, it may not be actively followed by major research firms. Investors should conduct their own due diligence and consider the company's financial condition, clinical trial progress, and competitive landscape before making any investment decisions. The company's negative P/E ratio and profit margin suggest caution.
What are the main risks for SXTP?
The main risks for 60 Degrees Pharmaceuticals include clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, and funding constraints. The company's success depends on the positive outcomes of its clinical trials for Tafenoquine and Celgosivir. Regulatory delays or rejections could significantly impact the company's prospects.
What are the key factors to evaluate for SXTP?
60 Degrees Pharmaceuticals, Inc. (SXTP) holds an AI score of 18/100 (low). 60 Degrees Pharmaceuticals presents a focused investment opportunity within the infectious disease treatment space. Not financial advice.
How frequently does SXTP data refresh on this page?
SXTP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SXTP's recent stock price performance?
60 Degrees Pharmaceuticals, Inc. (SXTP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SXTP overvalued or undervalued right now?
60 Degrees Pharmaceuticals, Inc. (SXTP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SXTP before investing?
Before investing in 60 Degrees Pharmaceuticals, Inc. (SXTP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's financial condition and clinical trial progress should be closely monitored.